Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
10:00pm, Tuesday, 22'nd Nov 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus to Present at the Piper Sandler 34th Annual Healthcare Conference
05:00pm, Tuesday, 22'nd Nov 2022
ROCKVILLE, Md., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
12:25am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus to Present at Two November Healthcare Conferences
10:30pm, Tuesday, 08'th Nov 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals (SUPN) Misses Q3 Earnings Estimates
09:04pm, Tuesday, 08'th Nov 2022
Supernus (SUPN) delivered earnings and revenue surprises of -90.63% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals, Inc. (SUPN) Q3 2022 Earnings Call Transcript
05:42pm, Tuesday, 08'th Nov 2022
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Exe
Supernus to Present at Two November Healthcare Conferences
05:30pm, Tuesday, 08'th Nov 2022
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
08:30pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 8, 2022
04:30pm, Tuesday, 25'th Oct 2022
ROCKVILLE, Md., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Provides Regulatory Update on SPN-830
12:30pm, Monday, 10'th Oct 2022 GlobeNewswire Inc.
ROCKVILLE, Md., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus to Present at the 2022 Wells Fargo Healthcare Conference
04:00pm, Wednesday, 31'st Aug 2022
ROCKVILLE, Md., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio
04:09am, Friday, 19'th Aug 2022
Shares have fallen by 30% over 5 years and have risen by 15% in 2022. CNS specialist has a rich 30+ year history, varied approved product portfolio and deep pipeline.
Best Momentum Stocks to Buy for August 8th
02:00pm, Monday, 08'th Aug 2022 Zacks Investment Research
CLH, NETI and SUPN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2022.
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q2 2022 Results - Earnings Call Transcript
08:10am, Sunday, 07'th Aug 2022
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
09:25pm, Thursday, 04'th Aug 2022 Zacks Investment Research
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
